DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Interpersonal Psychotherapy for Treatment Resistant Depression

Information source: Hospital de Clinicas de Porto Alegre
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Treatment Resistant Depression

Intervention: IPT+ antidepressant drugs (Other); fluoxetine (Drug); sertraline (Drug); paroxetine (Drug); Citalopram (Drug); escitalopram (Drug); fluvoxamine (Drug); Venlafaxine (Drug); Duloxetine (Drug); Bupropion (Drug); Lithium (Drug); Risperidone (Drug); tranylcypromine (Drug); Imipramine (Drug); amitriptyline (Drug); Clomipramine (Drug); nortriptyline (Drug); trazodone (Drug); Mirtazapine (Drug); sulpiride (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Hospital de Clinicas de Porto Alegre

Official(s) and/or principal investigator(s):
Marcelo PA Fleck, MD,PhD, Principal Investigator, Affiliation: Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre

Overall contact:
Livia H Souza, MD, Phone: +55 51 98658701, Email: liviahartmanndesouza@gmail.com

Summary

The purpose of this study is to determine whether combination of antidepressant drugs plus interpersonal psychotherapy is superior to antidepressant drugs alone in treatment resistant depression.

Clinical Details

Official title: Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Hamilton Depression Scale (HAM-D) - continuous

Secondary outcome: Beck depression Inventory (BDI)

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Primary diagnose of unipolar treatment resistant depression

Exclusion Criteria:

- Patients diagnose of: bipolar disorder, psychosis, high suicide risk, Intellectual

disability, illicit drug dependence.

- Currently in or having received psychotherapy in the last 4 weeks

Locations and Contacts

Livia H Souza, MD, Phone: +55 51 98658701, Email: liviahartmanndesouza@gmail.com

Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS 90035-003, Brazil; Recruiting
Lívia H Souza, MD, Phone: +55 5198658701, Email: livia.hs@terra.com.br
Marcelo PA Fleck, MD, PhD, Phone: +55 51 33598294, Email: mfleck.voy@terra.com.br
Lívia H Souza, MD, Sub-Investigator
Marcelo PA Fleck, MD, PhD, Principal Investigator
Marco Antonio K Caldieraro, MD, MSc, Sub-Investigator
Lucas Spanemberg, MD, Sub-Investigator
Edgar A Vares, MD, Sub-Investigator
Additional Information

Starting date: April 2013
Last updated: July 10, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017